All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: BupiZenge
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Baltic Sea Foundation
Deal Size: $8.3 million Upfront Cash: Undisclosed
Deal Type: Financing November 16, 2020
Details:
OncoZenge is developing the BUPI project under the BupiZenge ® brand , for the treatment of pain due to oral mucositis, a serious side effect of cancer treatment. BupiZenge ® has shown promising results in a phase 2 study. The capital will be used to finance the phase 3 study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IRL752
Therapeutic Area: Neurology Product Name: IRL752
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
IRL752 is a drug candidate in clinical Phase II and is in development by IRLAB for the treatment of impaired balance (postural dysfunction) and falls in Parkinson's disease (PD-Falls).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IRL752
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2020
Details:
The results from the clinical phase IIa study, now published, indicate that IRL752 has the potential to improve balance and reduce the risk of falls.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2020
Details:
WHO concluded that IRL790 is wholly unique in its mechanism of action and has, therefore, given IRL790 a new INN.